-
公开(公告)号：KR1020090112150A
公开(公告)日：2009-10-28
申请号：KR1020080037868
申请日：2008-04-23
Applicant: 한국화학연구원
CPC classification number: A61L27/52 , A61K9/2866 , A61K47/38 , A61K47/50
Abstract: PURPOSE: A thermo sensitive hydrogel containing anionic polymers and cationic polymers is provided, which improves engraft capability of the various cell like a chondrocyte. CONSTITUTION: A thermo sensitive hydrogel is thermo sensitivity type hydrogel by the static attraction of the anionic polymer and cationic polymer which have the bio compatibility. The anionic polymer is the carboxymethyl cellulose and has viscosity of 50-3,000 cP. The cationic polymer is more than one kind selected from polyethyleneimine, sparteine, spermidine, spermine, phenylpropanolamine, triethanolammine, epinephrine, and serotonin and has the molecular weight of 10-60,000 g/mol.
Abstract translation: 目的：提供含有阴离子聚合物和阳离子聚合物的热敏水凝胶，可改善各种细胞如软骨细胞的移植能力。 构成：热敏水凝胶是具有生物相容性的阴离子聚合物和阳离子聚合物的静电吸引的热敏型水凝胶。 阴离子聚合物为羧甲基纤维素，粘度为50-3,000cP。 阳离子聚合物是选自聚乙烯亚胺，亚巴碱，亚精胺，精胺，苯丙醇胺，三乙醇胺，肾上腺素和5-羟色胺中的多种，分子量为10-60,000g / mol。
-
公开(公告)号：KR100580577B1
公开(公告)日：2006-05-16
申请号：KR1020030064633
申请日：2003-09-18
Applicant: 한국화학연구원
Abstract: 본 발명은 자가 미세 유화형 약물 전달 시스템을 이용하는 약물 조성물에 관한 것으로서, 상기 약물 조성물은 소염 진통제의 활성 성분 1 내지 40 중량%; 계면활성제 5 내지 50 중량%; 용해제 10 내지 50 중량%; 공계면활성제 10 내지 50 중량%; pH 조절제 0.1 내지 5 중량%; 및 항산화제 1 내지 5 중량%를 포함하는 나노 에멀젼 농축액을 포함하는 자가 미세 유화형 약물 전달 시스템을 이용하는 것이다.
본 발명의 핵심은 소염 진통제인 덱시부프로펜을 자가미세유화형 약물전달시스템에 적용하여 신속한 약효를 발현하고 부작용을 최소화하는 방법으로서 다수의 산업 재산권 획득 이외에도 국내 기술의 자립성, 신기술의 축적뿐만 아니라 기술 수출로 이어질 것으로 예상된다.
덱시부프로펜,나노에멀젼농축액,용해제,계면활성제,공계면활성제,자가미세유화형 약물전달시스템,연질캡슐제,pH조절제,항산화제.-
公开(公告)号：KR1020090055455A
公开(公告)日：2009-06-02
申请号：KR1020080030876
申请日：2008-04-02
Applicant: 한국화학연구원
Abstract: A method for differentiating an adult stem cell to a nerve cell using a small molecule compound is provided to treat central nervous disease such as Parkinson disease, dementia, alzheimer disease, and spinal cord injury. An adult stem cell is differentiated to a nerve cell using a small molecule compound as an inducer. The adult stem cell is derived from a bone marrow, skeletal muscle or adipose tissue. A small compound is a histon deacetylase inhibitor and comprises alkylthiobenximidazole compound, benzhydroxyamide compound, quinozaline hydrozamide compound, or acylaminomethyl hydroximide. A composition for treating the nerve disease comprises a differentiated nerve cell using the inducer. The nerve disease is Parkinson disease, dementia, Alzheimer disease, or spinal cord injury.
Abstract translation: 提供使用小分子化合物将成体干细胞分化为神经细胞的方法，用于治疗中枢神经疾病如帕金森病，痴呆，阿尔茨海默病和脊髓损伤。 使用小分子化合物作为诱导剂将成体干细胞分化成神经细胞。 成体干细胞衍生自骨髓，骨骼肌或脂肪组织。 一种小化合物是一种组蛋白脱乙酰酶抑制剂，它包括烷基硫代噻肟化合物，苯甲酰胺化合物，喹喔啉氢化物酰胺化合物或酰氨基甲基氢化物。 用于治疗神经疾病的组合物包括使用诱导剂的分化神经细胞。 神经疾病是帕金森病，痴呆，阿尔茨海默病或脊髓损伤。
-
公开(公告)号：KR1020080075387A
公开(公告)日：2008-08-18
申请号：KR1020070014505
申请日：2007-02-12
Applicant: 한국화학연구원
IPC: A61L27/52 , A61L27/54 , A61L27/36 , A61K35/545 , A61L27/38
CPC classification number: A61L27/52 , A61K35/545 , A61L27/3629 , A61L27/3878 , A61L27/54
Abstract: Development of tissue engineered scaffolds for nerve regeneration using biocompatible and injectable hydrogel is provided to regenerate the central nerve by compounding a stem cell and a physiological active material to the scaffold. Development of tissue engineered scaffolds for nerve regeneration using biocompatible and injectable hydrogel includes a biocompatible scaffold compounded with an adult stem cell and a physiological active material, and comprising an injectable hydrogel of biocompatible and temperature-sensitive polyethylene glycol/biodegradable polyesters block copolymers or biocompatible porcine small intestinal sub-mucosa powder with phase transition behavior.
Abstract translation: 提供使用生物相容性和可注射水凝胶进行神经再生的组织工程支架的开发，以通过将干细胞和生理活性物质混合到支架上来再生中枢神经。 使用生物相容性和可注射的水凝胶开发用于神经再生的组织工程支架包括与成体干细胞和生理活性物质混合的生物相容性支架，并且包括生物相容性和温度敏感性聚乙二醇/可生物降解聚酯嵌段共聚物或生物相容性猪的可注射水凝胶 具有相变行为的小肠粘膜下层粉末。
-
公开(公告)号：KR100832552B1
公开(公告)日：2008-05-26
申请号：KR1020060125541
申请日：2006-12-11
Applicant: 한국화학연구원
IPC: A61K9/08 , A61K31/765
CPC classification number: A61K47/34 , A61K9/0019 , A61K9/06 , A61K38/28 , A61K38/38
Abstract: An injection formulation of a drug is provided to release a desired amount of the drug gradually for a desired time to a portion desired by a drug person administered to the drug by using a bio-compatible and thermosensitive polyethyleneglycol/polyester block copolymer to make the drug semi-solid or gel. An injection formulation comprises a hydrophilic portion consisting of polyethyleneglycol having a molecular weight of 350-2,000g/mole and a biodegradable polyester hydrophobic portion containing a caprolactone(CL) segment as an essential ingredient and at least one of a paradioxanone(PDO) segment and a trimethylene carbonate(TMC) segment and is characterized in that it is prepared by mixing a protein or peptide-based drug with a bio-compatible and thermosensitive polyethyleneglycol/biodegradable polyester block copolymer having a molecular weight of 2,000-7,000g/mole, wherein the protein or peptide-based drug is albumin, calcitonin, octreotide, leuprolide, adenosine deaminase, L-asparaginase, urokinase, interferon alpha-2b, interferon beta-1b, human insulin, insulin-like growth factor-1(IGF-1), erythropoietin(EPO), granulocyte colony stimulating factor(G-CSF), human growth hormone(hGH), nerve growth factor(NGF), brain-derived neurotrophic factor(BDNF), neurotrophin-3(NT-3), fibroblast growth factor(FGF), epidermal growth factor(EGF), endothelial growth factor(VEGF), transforming growth factor-beta(TGF-beta) or platelet-derived growth factor(PDGF).
Abstract translation: 提供药物的注射制剂，通过使用生物相容性和热敏性聚乙二醇/聚酯嵌段共聚物将所需量的药物逐渐释放到药物给药的人所需的部分，以制备药物 半固体或凝胶。 注射制剂包含由分子量为350-2,000g / mol的聚乙二醇组成的亲水部分和含有己内酯（CL）链段作为必需成分的可生物降解的聚酯疏水部分和至少一种对二恶烷酮（PDO）链段和 一种三亚甲基碳酸酯（TMC）片段，其特征在于其通过将蛋白质或肽基药物与分子量为2,000-7,000g / mol的生物相容性和热敏聚乙二醇/可生物降解的聚酯嵌段共聚物混合而制备，其中 蛋白质或肽类药物是白蛋白，降钙素，奥曲肽，亮丙瑞林，腺苷脱氨酶，L-天冬酰胺酶，尿激酶，干扰素α-2b，干扰素β-1b，人胰岛素，胰岛素样生长因子-1（IGF-1） ，红细胞生成素（EPO），粒细胞集落刺激因子（G-CSF），人生长激素（hGH），神经生长因子（NGF），脑源性神经营养因子（BDNF），神经营养因子-3（NT-3），成纤维细胞 生长因子（FGF），表皮生长因子（EGF），内皮生长因子（VEGF），转化生长因子-β（TGF-β）或血小板衍生生长因子（PDGF）。
-
Patent Agency Ranking
公开(公告)号：KR100764890B1
公开(公告)日：2007-10-09
申请号：KR1020050108754
申请日：2005-11-14
Applicant: 한국화학연구원
Abstract: 본 발명은 폴리에틸렌이민과 인지질을 접합하여 제조된 리포솜을 이용한 항암주사제 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 세포내 이입 효율을 증가시키기 위한 물질로서 폴리에틸렌이민을 인지질과 접합하여 폴리에틸렌이민이 접합된 양이온성 리포솜을 제조하고, 이를 치료하고자 하는 부위(종양)에 직접 주사하여 음전하를 띄는 종양세포 표면에 정전기적으로 흡착시켜 항암제가 함유된 리포솜이 치료하고자 하는 부위에 고정화되어 그 부위에서만 약물이 방출되도록 유도함으로써 약물의 부작용을 사전에 방지하여 체내 안전성을 향상시킬 수 있는 국소 투여용 항암주사제로서 폴리에틸렌이민과 인지질을 접합하여 제조된 리포솜의 제조방법에 관한 것이다.
폴리에틸렌이민, 인지질, 리포솜, 국소 투여용 항암주사제-
公开(公告)号：KR1020060099740A
公开(公告)日：2006-09-20
申请号：KR1020050021150
申请日：2005-03-14
Applicant: 한국화학연구원
CPC classification number: B82Y5/00 , A61K49/1854
Abstract: 본 발명은 수용성 산화철 나노 입자 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 산화철 전구체의 열분해법을 이용하여 정맥내 투여가 가능한 생체 적합적 고분자인 폴리비닐피롤리돈을 산화철 나노 입자 표면에 코팅함으로써 입자 크기를 제어할 수 있고 물에 잘 녹는 균일한 크기의 산화철 나노 입자를 제조하는 방법과 폴리비닐피롤리돈이 코팅된 수용성 산화철 나노 입자에 관한 것이다. 상기 수용성 산화철 나노 입자는 뛰어난 조영 효과를 가짐으로써 MRI 조영제로서 활용이 가능하다.
산화철, 나노 입자, 산화철 전구체, 열분해법, 폴리비닐피롤리돈, 코팅, MRI 조영제-
8.发明公开
公开(公告)号：KR1020050020179A
公开(公告)日：2005-03-04
申请号：KR1020030057918
申请日：2003-08-21
Applicant: 한국화학연구원
IPC: A61K9/00
CPC classification number: A61K9/5042 , A61K9/5026 , A61K31/4422
Abstract: PURPOSE: A composition for producing sustained-release porous membrane for oral drug delivery system and the oral drug delivery system using the same sustained-release porous membrane are provided, which oral drug delivery system controllably and continuously releases drugs, reduces the coating cost by using a smaller amount of porous membrane, and has improved storage stability against humidity and temperature. CONSTITUTION: The composition for producing sustained-release porous membrane for oral drug delivery system comprises one or more film forming materials selected from cellulose-based compound, polymethacrylate, semipermeable polyamide and semipermeable sulfonated polystyrene; the film forming material comprises cellulose acetate and polymethylmethacrylate in a weight ratio of 2 -3:1-1.5. The oral drug delivery system comprises 0.1 to 50 parts by weight of a core containing pharmaceutical active components; and the sustained-release porous membrane containing one or more film forming materials selected from cellulose-based compound, polymethacrylate, semipermeable polyamide, semipermeable polyurethane and semipermeable sulfonated polystyrene.
Abstract translation: 目的：提供一种用于口服药物递送系统的缓释多孔膜的制造用组合物和使用该缓释多孔膜的口服药物输送系统，该口服药物输送系统可控地连续地释放药物，通过使用 少量的多孔膜，并且改善了对湿度和温度的储存稳定性。 构成：用于制备口服药物递送系统的缓释多孔膜的组合物包含一种或多种选自纤维素类化合物，聚甲基丙烯酸酯，半透性聚酰胺和半透性磺化聚苯乙烯的成膜材料; 该成膜材料包括重量比为2-3：1-1.5的乙酸纤维素和聚甲基丙烯酸甲酯。 口服药物递送系统包含0.1至50重量份的含有药物活性组分的核心; 以及含有一种或多种选自纤维素类化合物，聚甲基丙烯酸酯，半透性聚酰胺，半透性聚氨酯和半透性磺化聚苯乙烯的成膜材料的缓释多孔膜。
-
公开(公告)号：KR1020090059880A
公开(公告)日：2009-06-11
申请号：KR1020070126961
申请日：2007-12-07
Applicant: 한국화학연구원
Abstract: A method for preparing a block copolymer is provided to prevent a catalyst component inside a copolymer chain from being left behind after reaction termination, to easily control molecular weight and to polymerize a cyclic ester monomer at a room temperature. A method for preparing a polyalkylene glycol/plyester block copolymer uses a strong acid catalyst with pKa which is not greater than 1 as a polymerization catalyst and polyalkylene glycol containing a hydroxyl group at a chain terminal part as an initiator. The method comprises a step of polymerizing at least one or two kinds of cyclic monomer at -70 ~25 °C for 12~24 hours to prepare the polyalkylene glycol/plyester block copolymer with the whole molecule amount of 1,000~100,000 g/mole. The at least one or two kinds of cyclic monomer are selected from ester series lactide segment, caprolactone segment and glycolide segment.
Abstract translation: 提供制备嵌段共聚物的方法，以防止共聚物链内部的催化剂组分在反应终止后留下，以容易地控制分子量并在室温下聚合环酯单体。 制备聚亚烷基二醇/聚丙烯酸酯嵌段共聚物的方法使用pKa不大于1的强酸催化剂作为聚合催化剂，在链端部分含有羟基的聚亚烷基二醇作为引发剂。 该方法包括在-70〜25℃下聚合至少一种或两种环状单体12〜24小时的步骤，以制备整个分子量为1,000〜100,000g / mol的聚亚烷基二醇/聚丙烯酸酯嵌段共聚物。 所述至少一种或两种环状单体选自酯系丙交酯链段，己内酯链段和乙交酯链段。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.024 seconds)
